GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » EV-to-EBITDA

Ludwig Enterprises (Ludwig Enterprises) EV-to-EBITDA : -45.89 (As of May. 22, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ludwig Enterprises's enterprise value is $36.25 Mil. Ludwig Enterprises's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.79 Mil. Therefore, Ludwig Enterprises's EV-to-EBITDA for today is -45.89.

The historical rank and industry rank for Ludwig Enterprises's EV-to-EBITDA or its related term are showing as below:

LUDG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -370.99   Med: 0   Max: 0
Current: -45.89

LUDG's EV-to-EBITDA is ranked worse than
100% of 488 companies
in the Medical Devices & Instruments industry
Industry Median: 16.21 vs LUDG: -45.89

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Ludwig Enterprises's stock price is $0.22. Ludwig Enterprises's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.001. Therefore, Ludwig Enterprises's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Ludwig Enterprises EV-to-EBITDA Historical Data

The historical data trend for Ludwig Enterprises's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises EV-to-EBITDA Chart

Ludwig Enterprises Annual Data
Trend Dec22 Dec23
EV-to-EBITDA
-172.63 -11.69

Ludwig Enterprises Quarterly Data
Sep22 Dec22 Sep23 Dec23
EV-to-EBITDA - - - -

Competitive Comparison of Ludwig Enterprises's EV-to-EBITDA

For the Medical Devices subindustry, Ludwig Enterprises's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ludwig Enterprises's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ludwig Enterprises's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ludwig Enterprises's EV-to-EBITDA falls into.



Ludwig Enterprises EV-to-EBITDA Calculation

Ludwig Enterprises's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=36.253/-0.79
=-45.89

Ludwig Enterprises's current Enterprise Value is $36.25 Mil.
Ludwig Enterprises's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ludwig Enterprises  (OTCPK:LUDG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ludwig Enterprises's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.22/-0.001
=At Loss

Ludwig Enterprises's share price for today is $0.22.
Ludwig Enterprises's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.001.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Ludwig Enterprises EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.